WilmerHale Advises Translate Bio on Collaboration with Sanofi Pasteur

Download IconDownload Print IconPrint

WilmerHale Advises Translate Bio on Collaboration with Sanofi Pasteur

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.

On March 27, 2020, Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, announced a collaboration to develop a novel mRNA vaccine for COVID-19 with Sanofi Pasteur, the vaccines global business unit of Sanofi. The two companies will jointly investigate multiple candidates with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development. This collaboration leverages an existing agreement from 2018 between Translate Bio and Sanofi Pasteur to develop mRNA vaccines for infectious diseases.

The WilmerHale team representing Translate Bio was led by Steve Singer, Ariel Soiffer and Cynthia Mazareas.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel